Fat-soluble vitamin
Vitamin D3 (Cholecalciferol)
Vitamin D3: its circulating metabolite 25-hydroxyvitamin D3 had a mean half-life of 15.1 days in a tracer study of 36 healthy men, and the app lists about 15 days (360 hours).1
Vitamin D3 (Cholecalciferol) after one dose: 50% at ~15 days, 25% at 30 days, 12.5% at 45 days.
Drawn from the half-life in the app's model, ~15 days. The model's figures
- Compound
- Vitamin D3 (Cholecalciferol)
- Symbol
- D3
- Family
- Supplements
- Parts
- 14
- References
- 14
- Checked
- Last reviewed . Sources are listed below.
Overview
Bikle's 2014 review in Chemistry and Biology describes vitamin D3 (cholecalciferol) as produced in the skin from 7-dehydrocholesterol when ultraviolet light breaks the B ring, and notes that vitamin D can also be obtained from the diet.2 A US DailyMed record from Rising Pharma lists a cholecalciferol 1000 IU (25 mcg) tablet sold as a dietary supplement, and its label carries the line "These statements have not been evaluated by the Food and Drug Administration."3
The app grades the evidence for vitamin D3 as strong. The three large trials described below name their funders as the National Institutes of Health and others (VITAL), the National Institute of Diabetes and Digestive and Kidney Diseases and others (D2d), and the National Health and Medical Research Council (D-Health).4,5,6
How it works
Sources in this part
Bikle writes that vitamin D "is metabolized first to 25 hydroxyvitamin D (25OHD), then to the hormonal form 1,25-dihydroxyvitamin D (1,25(OH)2D)".2 In the review, "CYP2R1 is the most important 25-hydroxylase; CYP27B1 is the key 1-hydroxylase", and both 25OHD and 1,25(OH)2D are catabolised by CYP24A1.2 The review states that "The liver has been established as the major if not sole source of 25OHD production from vitamin D" and that "The kidney is the major if not the sole source of circulating levels of 1,25(OH)2D".2 The review reports "thousands of these binding sites regulating hundreds of genes in a cell-specific fashion" for the vitamin D receptor, which 1,25(OH)2D activates.2
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~15 days
- Bioavailability
- 95%
- Typical dose
- 2000–5000 IU/day
- Route
- Oral
- Time to peak
- ~12 h
The second column of the table holds the app's own figures, shown beside what the sources report. The app's note states that the half-life of approximately 15 days applies to the 25-hydroxyvitamin D metabolite.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~15 days (360 h) | 25(OH)D3: mean 15.1 days (SD 3.1) in 36 healthy men given an oral tracer; a review gives about 15 days for 25(OH)D3 and about 2 months for vitamin D itself; serum vitamin D3 after a single oral 900 µg dose: mean 31.4 h (SEM 3.3) in 10 healthy participants1,7,8 |
| Bioavailability | 95% | An absolute oral bioavailability percentage for cholecalciferol was not identified in the sources read; in a crossover trial of 900 µg oral vitamin D3, 6 malabsorptive patients had 64% lower AUC than 10 healthy participants (1177 ± 425 against 3258 ± 496 ng · h/mL, means ± SEMs)7 |
| Time to peak | ~12 h | Serum vitamin D3 after a single oral 900 µg dose peaked at a mean of 10.4 h (SEM 0.7) in 10 healthy participants7 |
| Route | Oral | Oral vitamin D3 was given in the crossover trial and, as capsules, in VITAL7,4 |
Level over 6 weeks
Level, as a share of the peak after one 100 mg dose
As studied: daily (VITAL 2000 IU per day; D2d 4000 IU per day)4, monthly (D-Health 60,000 IU per month)6.
An illustration from a pharmacokinetic model using a half-life of 360 hours (15 days). It is not a measured level or a suggested dose.
Deeper analysis: the 25(OH)D half-life tracer study
Jones and colleagues reported the tracer study in the Journal of Clinical Endocrinology and Metabolism in 2014, with 18 healthy men in The Gambia and 18 in the United Kingdom.1 Each man received an oral tracer dose of deuterated 25(OH)D2 and 25(OH)D3 (both 40 nmol) with blood collected over 33 days, so the 15.1-day figure describes the 25-hydroxylated metabolite rather than a dose of cholecalciferol.1 The 25(OH)D3 half-life was longer than that of 25(OH)D2 in the combined group (13.9 days, SD 2.6), and the authors report that this was "not in the United Kingdom [15.1 (2.4) d vs 15.6 (2.5) d; P = .3]".1 Their stated limitations include that "The sample size was small and may have limited the ability to find significant relationships, particularly for different genotypes", and the study was restricted to "healthy, young men of similar BMI".1 The work was "jointly supported by the Medical Research Council" and the Department for International Development, and the disclosure summary reads "The authors have nothing to declare".1
Deeper analysis: oral vitamin D3 against 25-hydroxyvitamin D3 in a crossover trial
Charoenngam and colleagues, with Holick as last author, reported a single-centre randomised, double-blind crossover trial in the American Journal of Clinical Nutrition in 2021.7 Six malabsorptive patients and 10 healthy participants each received 900 µg of oral vitamin D3 and 900 µg of oral 25(OH)D3, assigned in random order, with the second dose at least 28 days after the first.7 After the vitamin D3 dose, the lower AUC in malabsorptive patients (1177 ± 425 against 3258 ± 496 ng · h/mL) remained significant after adjustment for potential confounders.7 After the 25(OH)D3 dose, AUC was not significantly different between the malabsorptive patients and the healthy participants (P = 0.540).7 When the 10 healthy participants were split by BMI, the higher-BMI group had a 53% lower vitamin D3 AUC, but "no significant difference in AUC between groups was observed after adjusting for baseline serum total 25(OH)D concentration and BMI in the ANCOVA model (P = 0.244)".7 The authors report that "No adverse reactions or signs of vitamin D toxicity (e.g., hypercalcemia, acute renal failure, polyuria, and kidney stones) were observed in any of the participants throughout the study".7 The authors name their own limitations: "this study has a relatively small sample size", and "it cannot be concluded with certainty that, compared with oral vitamin D3, the ability of oral 25(OH)D3 to increase serum 25(OH)D3 is significantly less compromised in malabsorptive patients".7 The trial "was funded in part by a grant from Carbogen Amcis BV", which also "provided assistance and the supply of vitamin D3 and 25-hydroxyvitamin D3", and the last author's disclosure states "MFH shares in a patent pending with Carbogen Amcis BV".7 The same disclosures state that Holick was a former consultant for Quest Diagnostics, Inc., a consultant for Ontometrics, Inc., and Biogena, Inc., and on the Speaker's Bureau for Abbott, Inc., and that Apovian reports personal fees from Nutrisystem, Zafgen, Sanofi-Aventis, Orexigen and other companies and grant funding from Aspire Bariatrics, GI Dynamics, Orexigen, Takeda and others, outside of the funded work.7
Human studies
The table lists the trials of vitamin D3 read for this compound, each with its placebo comparator and stated dose.
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Manson and colleagues, VITAL, New England Journal of Medicine 20194 | Randomised, placebo-controlled factorial trial; funded by the National Institutes of Health and others; Pharmavite donated the vitamin D4 | 25,871 US men aged 50 or older and women aged 55 or older4 | Vitamin D3 2000 IU per day or placebo; median follow-up 5.3 years4 | Cancer hazard ratio 0.96 (95% CI 0.88 to 1.06; P=0.47); major cardiovascular events 0.97 (95% CI 0.85 to 1.12; P=0.69); death from any cause 0.99 (95% CI 0.87 to 1.12); no excess risk of hypercalcemia identified4 |
| Pittas and colleagues, D2d, New England Journal of Medicine 20195 | Multicentre, randomised, placebo-controlled trial; supported mainly by the NIDDK and the Office of Dietary Supplements5 | 2423 adults at high risk for type 2 diabetes, not selected for vitamin D insufficiency5 | Vitamin D3 4000 IU per day or placebo; median follow-up 2.5 years5 | Diabetes in 293 against 323 participants, hazard ratio 0.88 (95% CI 0.75 to 1.04; P = 0.12); exploratory per-protocol hazard ratio 0.84 (95% CI 0.71 to 1.00); 47 (3.9%) against 37 (3.1%) stopped trial pills because of an adverse event5 |
| Neale and colleagues, D-Health, Lancet Diabetes and Endocrinology 20226 | Randomised, double-blind, placebo-controlled trial; funded by the National Health and Medical Research Council6 | 21,315 Australians aged 60 years or older (10,662 vitamin D, 10,653 placebo)6 | Vitamin D3 60,000 IU once a month or placebo, for 5 years; median follow-up 5.7 years6 | 1100 deaths (placebo 538, 5.1%; vitamin D 562, 5.3%); all-cause mortality hazard ratio 1.04 (95% CI 0.93 to 1.18; p=0.47); cancer mortality hazard ratio 1.15 (95% CI 0.96 to 1.39; p=0.13); exploratory analysis excluding the first 2 years, cancer mortality hazard ratio 1.24 (95% CI 1.01 to 1.54; p=0.05)6 |
| LeBoff and colleagues, VITAL fracture study, New England Journal of Medicine 20229 | Ancillary study of VITAL; funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases9 | 25,871 participants, not recruited on the basis of vitamin D deficiency, low bone mass or osteoporosis9 | Vitamin D3 2000 IU per day or placebo; median follow-up 5.3 years9 | Total fractures in 769 of 12,927 (vitamin D) against 782 of 12,944 (placebo), hazard ratio 0.98 (95% CI 0.89 to 1.08; P = 0.70); nonvertebral hazard ratio 0.97 (0.87 to 1.07); hip hazard ratio 1.01 (0.70 to 1.47); no substantial between-group differences in adverse events as assessed in the parent trial9 |
| Okereke and colleagues, VITAL-DEP, JAMA 202010 | Ancillary study of VITAL; grants from National Institutes of Health institutes10 | 18,353 men and women aged 50 years or older (9181 vitamin D3, 9172 placebo)10 | Vitamin D3 2000 IU per day or placebo; median treatment duration 5.3 years10 | Depression or clinically relevant depressive symptoms in 609 (vitamin D3) against 625 (placebo) participants, hazard ratio 0.97 (95% CI 0.87 to 1.09; P = .62); mean change in PHQ-8 score not significantly different from zero10 |
| Pilz and colleagues, Hormone and Metabolic Research 201111 | Randomised controlled trial; testosterone analysed in a subset of men; no funding statement in the PubMed record11 | Healthy overweight men in a weight-reduction program with 25(OH)D in the deficiency range; 165 of 200 participants, including 54 men, completed the trial11 | Vitamin D (form not specified in the record) 83 µg (3,332 IU) daily for 1 year (n = 31) or placebo11 | Compared with baseline, total testosterone rose from 10.7 ± 3.9 to 13.4 ± 4.7 nmol/l in the vitamin D group, with no significant change in any testosterone measure in the placebo group; changes are reported against each group's own baseline11 |
Deeper analysis: VITAL
Manson and colleagues, working at Brigham and Women's Hospital, Harvard Medical School and the Harvard T.H. Chan School of Public Health, reported VITAL in the New England Journal of Medicine in 2019.4 Participants had no history of cancer (except non-melanoma skin cancer) or cardiovascular disease, agreed to limit other vitamin D to 800 IU per day, and completed a three-month placebo run-in; their mean age was 67.1 years and 51% were women.4 The primary endpoints were total invasive cancer and major cardiovascular events (myocardial infarction, stroke and cardiovascular death), analysed by intention to treat, and adherence (at least two thirds of capsules) averaged 82.0% on vitamin D and 80.3% on placebo.4 The secondary results were also null at the 95% level: cancer death (341 deaths) hazard ratio 0.83 (95% CI 0.67 to 1.02), breast cancer 1.02 (0.79 to 1.31), prostate cancer 0.88 (0.72 to 1.07), colorectal cancer 1.09 (0.73 to 1.62), myocardial infarction 0.96 (0.78 to 1.19), stroke 0.95 (0.76 to 1.20) and cardiovascular death 1.11 (0.88 to 1.40).4 In an analysis excluding 1 and 2 years of follow-up that "was not specified in the protocol", cancer mortality hazard ratios were 0.79 (0.63 to 0.99) and 0.75 (0.59 to 0.96).4 For adverse events, the paper states "There were no significant increases in diagnoses of hypercalcemia, kidney stones, or gastrointestinal symptoms between treatment groups".4 The authors list as limitations "Median treatment duration was 5.3 years", that "The trial tested only one vitamin D dose", and that "Our power for site-specific analyses was limited".4 The funding statement says the National Institutes of Health sponsors "had a collaborative role in the design and conduct of the study and interpretation of the data", and that Pharmavite donated the vitamin D.4 The text read lists no individual author disclosures; it states "All authors completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest".4 The registry entry names Brigham and Women's Hospital as lead sponsor and shows an overall status of ACTIVE_NOT_RECRUITING.12
Deeper analysis: D2d
Pittas and colleagues reported D2d in the New England Journal of Medicine in 2019.5 Adults were eligible if they met at least two of three glycemic criteria for prediabetes and had no diagnostic criteria for diabetes, "regardless of the baseline serum 25-hydroxyvitamin D level".5 The primary outcome was new-onset diabetes, and participants were asked to limit outside vitamin D to 1000 IU per day.5 The primary result was a hazard ratio of 0.88 (95% CI 0.75 to 1.04; P = 0.12), and the authors conclude that vitamin D3 at 4000 IU per day "did not result in a significantly lower risk of diabetes than placebo".5 In a post hoc analysis of 103 participants with a baseline 25-hydroxyvitamin D below 12 ng per milliliter the hazard ratio was 0.38 (95% CI 0.18 to 0.80), against 0.92 (95% CI 0.78 to 1.08) in the other 2319.5 For safety, there were "no significant between-group differences in the protocol-specified adverse events of interest": hypercalcemia, a fasting urine calcium:creatinine ratio of more than 0.375, a low estimated glomerular filtration rate, and nephrolithiasis.5 The authors give as limitations that "The high percentage of participants with adequate levels of vitamin D may have limited the ability of the trial to detect a significant effect", that they "powered our trial to detect a 25% lower risk of diabetes", and that "The 24-hour urine calcium level was not measured".5 Funding came primarily from the NIDDK and the Office of Dietary Supplements of the National Institutes of Health, with secondary funding from the American Diabetes Association.5 The disclosures include grant support from Pfizer and DSM paid to Tufts University for Dawson-Hughes and grant support from DSM for Ceglia, and the NIDDK project scientist is a member of the D2d Research Group.5
Deeper analysis: D-Health
Neale and colleagues, based at QIMR Berghofer Medical Research Institute in Brisbane with co-authors at other Australian universities, reported D-Health in the Lancet Diabetes and Endocrinology in 2022.6 Participants were recruited across Australia from the Commonwealth electoral roll and received one oral gel capsule of 60,000 IU vitamin D3 or placebo once a month for 5 years, with all-cause mortality as the primary endpoint.6 The authors conclude that "Administering vitamin D3 monthly to unscreened older people did not reduce all-cause mortality", and that "Point estimates and exploratory analyses excluding the early follow-up period were consistent with an increased risk of death from cancer".6 The hazard ratio for cardiovascular disease mortality was 0.96 (95% CI 0.72 to 1.28; p=0.77) and for mortality from other causes 0.83 (95% CI 0.65 to 1.07; p=0.15).6 The PubMed record read for this study is a summary; it contains no separate limitations section, so limitations beyond the authors' interpretation were not read. The record's declaration of interests states "PMW has funding from AstraZeneca for an unrelated study of ovarian cancer" and that one author reports grants and honoraria from Amgen, Sanofi, Novartis, Eli-Lilly and Alexion.6
What a clinical practice guideline states
The Endocrine Society's 2024 guideline (Demay and colleagues, Journal of Clinical Endocrinology and Metabolism) states that the panel "suggests against empiric vitamin D supplementation above the current DRI to lower the risk of disease in healthy adults younger than 75 years", and its conclusion suggests empiric vitamin D "for those aged 1 to 18 years and adults over 75 years of age, those who are pregnant, and those with high-risk prediabetes".13 The record lists the Endocrine Society as the grant source.13 The PubMed record read for the guideline carries no author disclosures, so ties of the panel members to industry were not read.
Doses reported in studies and on labels
The app's typical dose is 2000 to 5000 IU per day by mouth; the table sets it beside the doses in the trials and on a US label.
| Setting | Dose and route | People and length | Reference |
|---|---|---|---|
| App's typical dose | 2000–5000 IU/day, oral | Not tied to a study | the app's figure |
| VITAL | Vitamin D3 2000 IU per day against placebo, oral capsule | 25,871 adults, median 5.3 years4 | VITAL |
| D2d | Vitamin D3 4000 IU per day against placebo, once-daily soft-gel | 2423 adults with prediabetes, median 2.5 years5 | D2d |
| D-Health | Vitamin D3 60,000 IU once a month against placebo, oral gel capsule | 21,315 Australians aged 60 or older, 5 years6 | D-Health |
| Testosterone trial | Vitamin D (form and route not stated in the record) 83 µg (3,332 IU) daily against placebo | Overweight men on a weight-reduction program, 1 year11 | Pilz 2011 |
| US label, Rising Pharma | One tablet contains 1000 IU (25 mcg); the label's suggested use is one tablet daily with water and a meal, for adults; its caution says to consult a doctor before use if pregnant, nursing, taking any medications or having any medical condition | Dietary supplement label3 | DailyMed label |
Side effects reported
In VITAL, "No excess risks of hypercalcemia or other adverse events were identified", and diagnoses of hypercalcemia, kidney stones and gastrointestinal symptoms did not differ significantly between groups.4 In D2d, 47 participants (3.9%) on vitamin D3 and 37 (3.1%) on placebo stopped trial pills because of an adverse event.5 In the VITAL fracture study, "There were no substantial between-group differences in adverse events as assessed in the parent trial", and the paper cites an Australian trial of 500,000 IU per year in which "very high oral doses of vitamin D" were associated with "an increased fracture risk among older women".9 In D-Health, the cancer-mortality hazard ratio for monthly 60,000 IU against placebo was 1.15 (95% CI 0.96 to 1.39; p=0.13), and the authors write that point estimates and exploratory analyses excluding the early follow-up period were "consistent with an increased risk of death from cancer".6 A review of the pharmacokinetics of toxicity states that animal experiments "have established that 25(OH)D(3) can reach concentrations up to 2.5 mumol/L, at which it is accompanied by hypercalcemia and other pathological sequelae resulting from a high Ca/PO(4) product", and that human reports of intoxication are "anecdotal".8
Bloodwork and markers
The app lists no health markers to monitor for vitamin D3. Bikle writes that "circulating levels of 25OHD are a useful marker of vitamin D nutrition", and the Charoenngam introduction states that "Measurement of serum 25(OH)D concentration is generally used for determining vitamin D status".2,7 Bikle cautions that standard mass spectrometry methods give a 25OHD "value increased above true levels to the extent that the sample contains the C-3 epimer", while immunoassays "by and large do not recognize the C-3 epimer".2 In VITAL, a subset of 1,644 participants had mean 25(OH)D rise from 29.8 ng/mL at baseline to 41.8 ng/mL at 1 year on 2000 IU per day, and D2d reported 27.7 ng/mL at baseline and 54.3 ng/mL at month 24 on 4000 IU per day.4,5 Jones writes that "current data support the viewpoint that the biomarker plasma 25(OH)D concentration must rise above 750 nmol/L to produce vitamin D toxicity", while "the more prudent upper limit of 250 nmol/L might be retained to ensure a wide safety margin".8 The Endocrine Society guideline states that "there was no clear evidence defining the optimal target level of 25(OH)D required for disease prevention in the populations considered" and suggests against routine 25(OH)D testing in those populations.13
Regulatory and anti-doping status
Sources in this part
The text of the World Anti-Doping Agency's 2026 Prohibited List, which takes effect on 1 January 2026, contains no entry for vitamin D, cholecalciferol or calciferol.14 The US record read for this compound is a dietary supplement label, which carries the statement "These statements have not been evaluated by the Food and Drug Administration".3 A regulator's tolerable upper intake level could not be read: the EFSA and National Academies pages returned access errors when fetched.
Storage and handling
Sources in this part
The Rising Pharma label for its 1000 IU tablet, the only label read, states "Store at room temperature and avoid excessive heat", "Keep tightly closed" and that the bottle "contains non-edible desiccant pack (s)".3
What is not known
Sources in this part
- An absolute oral bioavailability percentage for cholecalciferol was not identified in the sources read, so the app's 95% has no figure from a source beside it.
- The Endocrine Society guideline states that "the optimal doses for empiric vitamin D supplementation remain unclear for the populations considered".13
- No trial of vitamin D3 together with vitamin K2 was among the sources read, and the sources read give no effect of meal timing or dietary fat on vitamin D3 absorption in these studies.
Frequently asked questions
What is the half-life of vitamin D3?
Jones and colleagues reported a mean 25-hydroxyvitamin D3 half-life of 15.1 days (SD 3.1) in 36 healthy men, and the app lists about 15 days (360 hours).1 A review gives the half-life of vitamin D itself as approximately 2 months and that of 25-hydroxyvitamin D3 as approximately 15 days.8 In a crossover trial of 10 healthy participants, serum vitamin D3 after a single oral 900 µg dose had a mean half-life of 31.4 hours (SEM 3.3).7
How long does vitamin D3 take to reach its peak level?
In a crossover trial of 10 healthy participants, serum vitamin D3 peaked at a mean of 10.4 hours (SEM 0.7) after a single oral 900 µg dose, and the app lists about 12 hours.7
Is vitamin D3 banned by WADA?
Vitamin D3 is not named in the text of the WADA 2026 Prohibited List as read.14
Did vitamin D3 lower cancer or cardiovascular events in the VITAL trial?
Did vitamin D3 lower the risk of type 2 diabetes in the D2d trial?
Does vitamin D3 raise testosterone?
In one randomised trial of overweight men in a weight-reduction program with 25(OH)D in the deficiency range, total testosterone compared with baseline rose from 10.7 to 13.4 nmol/l in the 31 men given 83 µg (3,332 IU) of vitamin D daily (form not specified in the record) for 1 year, with no significant change in any testosterone measure in the placebo group.11 The authors wrote that supplementation "might increase testosterone levels" and that further randomised trials were warranted.11
Can vitamin D3 cause hypercalcemia?
In VITAL at 2000 IU per day the paper reports no significant increases in diagnoses of hypercalcemia between groups; in D2d at 4000 IU per day hypercalcemia was recorded in 5 events on vitamin D3 and 3 on placebo (incidence rate ratio 1.62, 95% CI 0.39 to 6.77), among protocol-specified adverse events with no significant between-group differences.4,5
Guides, tools and comparisons
References
- Jones KS, et al. 25(OH)D2 half-life is shorter than 25(OH)D3 half-life and is influenced by DBP concentration and genotype. J Clin Endocrinol Metab 2014. PMID 24885631
- Bikle DD. Vitamin D metabolism, mechanism of action, and clinical applications. Chem Biol 2014. PMID 24529992
- Rising Pharma Holdings. Cholecalciferol (Vitamin-D3) tablet, 1000 IU (25 mcg), dietary supplement. US label, DailyMed, issued 09/2026. DailyMed label
- Manson JE, et al. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. N Engl J Med 2019. PMID 30415629
- Pittas AG, et al. Vitamin D Supplementation and Prevention of Type 2 Diabetes. N Engl J Med 2019. PMID 31173679
- Neale RE, et al. The D-Health Trial: a randomised controlled trial of the effect of vitamin D on mortality. Lancet Diabetes Endocrinol 2022. PMID 35026158
- Charoenngam N, et al. A pilot-randomized, double-blind crossover trial to evaluate the pharmacokinetics of orally administered 25-hydroxyvitamin D3 and vitamin D3 in healthy adults with differing BMI and in adults with intestinal malabsorption. Am J Clin Nutr 2021. PMID 34008842
- Jones G. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr 2008. PMID 18689406
- LeBoff MS, et al. Supplemental Vitamin D and Incident Fractures in Midlife and Older Adults. N Engl J Med 2022. PMID 35939577
- Okereke OI, et al. Effect of Long-term Vitamin D3 Supplementation vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial. JAMA 2020. PMID 32749491
- Pilz S, et al. Effect of vitamin D supplementation on testosterone levels in men. Horm Metab Res 2011. PMID 21154195
- ClinicalTrials.gov. Vitamin D and Omega-3 Trial (VITAL), NCT01169259. Registry entry, status verified 2026-07. NCT01169259
- Demay MB, et al. Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2024. PMID 38828931
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list